About Parabilis Medicines Parabilis Medicines is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking biologically important targets long considered undruggable. The company has pioneered a new class of alpha-helical peptides – Helicons™ – capable of modulating intracellular proteins that have historically been beyond the reach of conventional medicines. The company’s lead investigational medicine, zolucatetide, is the first and only direct inhibitor of the β-catenin:TCF interaction, a central node in the Wnt/β-catenin pathway that has eluded drug developers for decades.

Zolucatetide is being evaluated in the clinic across multiple Wnt/β-catenin-driven diseases, including desmoid tumors, familial adenomatous polyposis (FAP) and a range of other solid tumor indications. Beyond zolucatetide, Parabilis is advancing additional Helicon-based programs focused on other challenging targets where we believe our medicines could have life-altering impact. com or follow us on LinkedIn .

What’s the opportunity? The Vice President, New Product Planning will play a key strategic leadership role in shaping the development and future direction of Parabilis Medicines’ portfolio. Reporting to the Chief Business & Strategy Officer, this individual will lead New Product Planning activities across the company’s pipeline, ensuring commercial, market, and strategic insights are integrated into critical program decisions throughout development.

This leader will partner cross-functionally across Clinical Development, Research, Regulatory, CMC, Business Development, and Executive Leadership to help define product and indication strategies, evaluate market opportunities, assess competitive dynamics, and inform long-term portfolio planning. The role is particularly critical as Parabilis advances zolucatetide (FOG-001) towards registrational Phase 3 study for desmoid tumor and pursue expansion indications including familial adenomatous polyposis (FAP), adamantinomatous craniopharyngioma (ACP), hepatocellular carcinoma (HCC) and a range of other Wnt/beta-catenin-driven solid tumors. The ideal candidate will bring a strong blend of commercial and marketing experience, strategic thinking, cross-functional leadership, scientific curiosity, and operational pragmatism, along with a passion for helping build innovative biotechnology companies.

Build scalable New Product Planning capabilities and processes to support the company’s long-term growth Lead New Product Planning activities for zolucatetide and future pipeline opportunities along with the team and lead or support future commercial readiness activities including launch preparation frameworks, go-to-market strategy development, and cross-functional alignment on pre-launch milestones and priorities. Partner closely with the Global Program Team and key functional leaders to incorporate commercial and market insights into development strategy, indication prioritization, and lifecycle planning. Assess market opportunities, competitive landscapes, unmet patient needs, and evolving standards of care across oncology and rare disease indications.

Help shape product positioning, differentiation, value proposition, pricing considerations, and future market development strategies. Provide strategic commercial input into portfolio prioritization, long-range planning, program strategy, business development, and key enterprise decision-making. Fostering a highly collaborative, roll-up-your-sleeves culture and be a mentor to team members.

Collaborate cross-functionally with Research, Regulatory, CMC, Finance, Corporate Strategy, and Business Development teams. Engage with patient advocacy groups, external experts, consultants, and key stakeholders to inform development and portfolio strategies.